Tumor targeting of baculovirus displaying a lymphatic homing peptide

Background Tumor‐associated cells and vasculature express attractive molecular markers for site‐specific vector targeting. To attain tumor‐selective tropism, we recently developed a baculovirus vector displaying the lymphatic homing peptide LyP‐1, originally identified by ex vivo / in vivo screening of phage display libraries, on the viral envelope by fusion to the transmembrane anchor of vesicular stomatitis virus G‐protein. Methods In the present study, we explored the specificity and kinetics of viral binding and internalization as well as in vivo tumor homing of the LyP‐1 displaying virus to elucidate the applicability of baculovirus for targeted therapies. Results We demonstrated that the LyP‐1 peptide contributes to saturable binding of baculovirus in human MDA‐MB‐435 and HepG2 carcinoma cells and escalates the kinetics of viral internalization leading to earlier nuclear accumulation and enhanced transgene expression. The LyP‐1 displaying virus also showed stronger competitiveness against transduction with wild‐type baculovirus, suggesting involvement of a specific receptor in cellular attachment and entry. Following intravenous injections, the modified virus accumulated within the human MDA‐MB‐435 and MDA‐MB‐231 carcinoma xenografts in mice with higher specificity and efficiency than the control virus. Targeting of the modified virus was more specific in the MDA‐MB‐435 than in the MDA‐MB‐231 xenografts as demonstrated by higher tumor accumulation and lower distribution in nontarget organs. No apparent cytotoxicity was associated with the surface modification. Conclusions This first demonstration of in vivo tumor targeting of a systemically administered, tropism‐modified baculoviral vector highlights the potential of baculovirus‐mediated targeted therapies. Copyright © 2008 John Wiley & Sons, Ltd.